ADR 002
Alternative Names: ADR-002; ADR-002KLatest Information Update: 28 Dec 2022
At a glance
- Originator Osaka University Hospital; Rohto Pharmaceutical
- Class Cardiovascular therapies; Gene therapies; Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiomyopathies
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for phase-I development in Cardiomyopathies(In the elderly, In adults) in Japan (Parenteral)